A pseudo-random patient sampling method evaluated

Abstract

Objective To compare two HIV cohorts to determine whether a pseudo-random sample can represent the entire study population. Study Design and Setting HIV-positive patients receiving care at 8 sites in 7 Asian countries. TAHOD pseudo-randomly selected a patient sample, while TAHOD-LITE included all patients. We compared patient demographics, CD4 count and HIV viral load testing for each cohort. Risk factors associated with CD4 count response, HIV viral load suppression (<400 copies/mL) and survival were determined for each cohort. Results There were 2318 TAHOD patients and 14714 TAHOD-LITE patients. Patient demographics, CD4 count and HIV viral load testing rates were broadly similar between the cohorts. CD4 count response and all-cause mortality were consistent among the cohorts with similar risk factors. HIV viral load response appeared to be superior in TAHOD and many risk factors differed, possibly due to viral load being tested on a subset of patients. Conclusions Our study gives the first empirical evidence that analysis of risk factors for completely ascertained endpoints from our pseudo-randomly selected patient sample may be generalized to our larger, complete population of HIV-positive patients. However, results can significantly vary when analysing smaller or pseudo-random samples, particularly if some patient data are not completely missing at random, such as viral load results.

Diabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD‐LITE) study

“…The 2017 TAHOD‐LITE data transfer gathered additional data on FPG and creatinine, and 10 of 20 TAHOD sites participated. Both studies have been described in more detail previously . Institutional Review Board approvals were obtained at all participating sites, the data management and analysis centre (The Kirby Institute, University of New South Wales Sydney, Sydney, Australia) and the coordinating centre (TREAT Asia/amfAR, Bangkok, Thailand).…”

Viral hepatitis and the cascade of care among people living with HIV in the Asia‐Pacific

“…Asia-Pacific, cascade of care, HBV, HCV, PLHIV, viral hepatitis transfer included data from over 46 000 adults living with HIV aged ≥18 years from 10 sites in Cambodia, Hong Kong SAR, India, Indonesia, South Korea, Thailand, and Vietnam. Methods and data transfer processes for TAHOD-LITE studies have previously been described [16][17][18]. Institutional review board approvals were obtained at all participating sites, the data management and analysis centre (The Kirby Institute, UNSW Sydney, Australia), and the coordinating centre (TREAT Asia/ amfAR, Bangkok, Thailand).…”

Cardio‐ankle vascular index of increased arterial wall stiffness is associated with neurocognitive impairment in well‐controlled HIV

“…However, even if it turns out that vascular dysfunction does not directly cause NCI, CAVI might still be a useful biomarker representing cumulative risk, regardless of whether the shared pathogenic factors are known. Next, pseudo‐randomization is commonly employed to recruit HIV cohorts, and epidemiological evidence indicates that such samples may be generalized to the larger populations from which they are drawn [51]. Nevertheless, this methodology inherently holds elements of a biased convenience sample.…”